Multiple Anti-Cancer Agents for Prostate Cancer

(PROSPECTOR Trial)

This trial tests the safety and effectiveness of different anti-cancer drugs for individuals with advanced prostate cancer that has spread. Participants will receive either a combination of two experimental drugs, one experimental drug alone, or a standard treatment called docetaxel, a chemotherapy drug. The trial seeks individuals with confirmed prostate cancer that has spread and no longer responds to standard hormone treatments. This study helps researchers understand the effectiveness of these new treatments and how patients tolerate them. As a Phase 1 and Phase 2 trial, it focuses on understanding the treatment's effects and measuring its effectiveness in an initial, smaller group, offering participants a chance to contribute to groundbreaking research.

The trial information does not specify if you need to stop taking your current medications. However, it does require that you have ongoing androgen deprivation therapy and a castrate level of serum testosterone. It's best to discuss your current medications with the trial team.

A previous study found the combination of AZD9574 and AZD2265 to be generally safe. Most patients tolerated the drugs well, even at higher doses. Although some patients experienced side effects, these were mostly mild, suggesting the combination is usually safe for patients.

Early research on AZD2265 alone shows it is also well-tolerated. Most patients did not experience serious side effects, even those with extensive prior treatments, indicating AZD2265 is likely safe for many people.

Researchers are excited about the treatments in this trial because they explore new combinations and applications of anti-cancer agents for prostate cancer. Unlike the standard treatment, which typically includes chemotherapy drugs like docetaxel, these investigational therapies include AZD9574 and AZD2265, which are administered in novel combinations. AZD9574 offers a unique mechanism by being taken daily alongside AZD2265, which could enhance its effectiveness. Additionally, AZD2265 is being tested both in combination and as a monotherapy, potentially providing more personalized treatment options. This trial could uncover more effective strategies by targeting cancer cells in different ways than traditional chemotherapy.

This trial will evaluate multiple anti-cancer agents for prostate cancer. Participants may receive a combination of AZD9574 and AZD2265, which studies have shown might help treat prostate cancer. Early lab tests demonstrated that these drugs work well together, showing strong effects against cancer. Another treatment arm will assess AZD2265 alone, which research suggests could be beneficial. Specifically, one study showed that AZD2265 helped some patients with advanced prostate cancer by shrinking their tumors and slowing disease progression. These findings suggest possible benefits for patients with metastatic prostate cancer, but further research is needed to confirm these results.¹⁴⁵⁶⁷